If you have read anything about GHK-Cu, you have probably read about what it does once it is inside skin: collagen signalling, gene expression, wound remodelling. What gets discussed far less is the step before that — whether a tripeptide painted onto intact skin actually gets past the outer layer at all. That question sits underneath almost every copper peptide claim on the market, and the GHK-Cu research on it is surprisingly blunt. This piece looks at what permeation studies show, why controlled cosmetic trials can still report real results, and where GHK-Cu sits legally in Australia.

For background on the compound itself, see our GHK-Cu profile.

What Is GHK-Cu, and Why Is Delivery the Hard Part?

GHK-Cu is glycyl-L-histidyl-L-lysine bound to a copper(II) ion — a three-amino-acid peptide with a molecular weight around 340 daltons. On paper that is small. Small usually means "gets through skin easily".

It does not, and the reason is chemistry rather than size. The stratum corneum — the outermost layer of dead, lipid-packed cells — is a lipophilic barrier. It is efficient at letting oily, uncharged molecules through and stubborn about hydrophilic, charged ones. GHK-Cu is water-loving and carries charge. A 2025 review in Molecules examining liposome-encapsulated GHK-Cu opens from exactly this premise: GHK-Cu is "fairly hydrophilic" with limited permeation through the lipophilic stratum corneum, which is why so much formulation work has gone into carriers in the first place.

That same review makes a second point worth sitting with. Despite years of commercial interest in liposomal copper peptides, the authors conclude that actual skin-permeation data for liposome-delivered GHK-Cu remains limited, and that the methods for measuring it are not yet standardised. In other words: the delivery systems are being sold faster than they are being measured.

The microneedle experiment that quantified it

The clearest number comes from a 2015 study in Pharmaceutical Research on microneedle-mediated delivery of copper peptide through skin. Researchers compared permeation across excised human skin with and without microneedle treatment.

Over nine hours through microneedle-treated skin: 134 ± 12 nanomoles of peptide and 705 ± 84 nanomoles of copper crossed. Through intact human skin: almost none of either.

Two things are worth noting, and neither is a marketing point.

First, this is an ex vivo laboratory model using excised skin in diffusion cells — it is not the same as a living, perfused, sebum-covered face, and it does not measure clinical outcomes. It tells you about transport, not benefit.

Second, the copper and the peptide did not cross in equal molar amounts — roughly five times more copper than peptide moved through. That is consistent with the complex not necessarily travelling intact, which matters if you are assuming "GHK-Cu delivered" when what may partly be delivered is copper ion plus peptide separately. The study did not resolve that question, and as far as we can find, no one has replicated it in living human skin.

So Why Do Cosmetic Trials Show Anything?

This is where the story gets more interesting than "copper peptides don't work".

There are controlled cosmetic studies — including double-blind, vehicle-controlled designs — reporting improvements in measures like skin thickness, hydration, elasticity and texture with topical GHK-Cu creams and carrier formulations over 8–12 weeks. Those studies exist and they are not nothing. But they measure skin outcomes, not peptide concentration in the dermis. Almost none of them confirm how much intact GHK-Cu reached viable tissue.

Several explanations are compatible with both sets of findings:

  • Reservoir effect. Peptide accumulating in the upper stratum corneum can still influence barrier behaviour and hydration without crossing into the dermis.
  • Appendageal routes. Hair follicles and sweat ducts bypass the main barrier, and a small percentage of surface area can carry a disproportionate share of transport.
  • Tiny amounts may be enough. A signalling peptide does not need bulk delivery to act; even sub-measurable quantities reaching viable epidermis could be biologically relevant. This is plausible rather than demonstrated.
  • The formulation itself. Vehicle-controlled designs help here, but occlusion, humectants and emulsifiers all shift measured "skin quality" outcomes.

The honest summary: topical GHK-Cu has the strongest human evidence base of any GHK-Cu route, and simultaneously the weakest published data on whether the active molecule actually arrives where the mechanism papers say it works. Both are true.

What this means for reading a label

A serum advertising a high GHK-Cu percentage is telling you about the jar, not about your skin. Concentration on the label and delivered dose are different variables, and the permeation literature suggests the gap between them is large. Formulation, carrier and whether the skin barrier is intact will do more than the number on the front.

It also explains why microneedling and copper peptides get paired so often in clinics and at-home routines. The 2015 data says that pairing genuinely changes transport. It also means you are bypassing a barrier — which raises irritation, sensitisation and infection considerations that a leave-on cream does not carry. That is a conversation for a qualified practitioner, not a blog.

Is GHK-Cu Legal in Australia? The Cosmetic and Injectable Split

Australia draws the line by claim and route, not by ingredient.

Topical GHK-Cu in a cosmetic is legal here. Cosmetic ingredients are regulated as industrial chemicals under AICIS, and products stay outside TGA jurisdiction as long as their claims describe appearance or cleansing rather than treating, preventing or curing a condition. The TGA's own guidance on determining whether a product is a cosmetic or a therapeutic good makes the trigger explicit: it is the therapeutic claim that moves a product into TGA territory. A copper peptide serum that says "improves the appearance of fine lines" is a cosmetic. One that says "treats scarring" is not.

Injectable GHK-Cu is a different matter entirely. On 13 April 2026 the TGA issued a safety advisory on unapproved peptide products, naming GHK-Cu alongside BPC-157, TB-500, retatrutide and CJC-1295 as examples frequently supplied in injectable form. These products are not on the Australian Register of Therapeutic Goods, have not been assessed for safety, quality or efficacy, and the TGA has flagged reports of severe allergic reactions. The regulator has named unapproved peptides a priority focus area, with seizures and penalties on the table.

It is worth stating plainly: there is no human randomised trial evidence for injected GHK-Cu. The entire regenerative case for systemic administration rests on cell-culture and animal work.

A note on registry listings

We regularly see GHK-Cu "Phase 2 trials" cited from clinical trial registries. Registry entries are submissions, not results — and at least one GHK-Cu wound-healing record currently circulating lists a sponsor we could not verify as a real organisation. A trial ID is not evidence. Check the sponsor exists, check the site exists, and check whether anything has actually been published.

You can browse how this compares with other compounds in our peptides library, or join the free updates list for new research as it lands.

FAQ

Does GHK-Cu actually penetrate the skin?

Passive penetration of intact GHK-Cu through undamaged skin appears to be very limited. A 2015 Pharmaceutical Research study found almost no peptide or copper crossed intact excised human skin over nine hours, while microneedle-treated skin allowed substantial permeation.

If it doesn't penetrate well, why do copper peptide creams have study data?

Controlled cosmetic trials measure skin outcomes like thickness, hydration and elasticity — not peptide concentration in the dermis. Effects may come from stratum corneum reservoir activity, follicular routes or very small delivered amounts; the mechanism has not been confirmed in those studies.

Is GHK-Cu legal in Australia?

Topical cosmetic use is legal and regulated through AICIS, provided the product avoids therapeutic claims. Injectable GHK-Cu is unapproved in Australia and was named in the TGA's April 2026 safety advisory on unapproved peptide products.

Does microneedling improve GHK-Cu absorption?

Laboratory data on excised human skin shows microneedle treatment dramatically increases both peptide and copper permeation compared with intact skin. Whether that translates to better clinical outcomes has not been established, and barrier disruption carries its own irritation and infection risks.

Sources

This article is independent editorial information, not medical advice. Topical GHK-Cu is legal in Australian cosmetics; injectable GHK-Cu is not approved by the TGA and was named in its April 2026 unapproved-peptides advisory. Speak to a qualified health professional before acting on anything here.